Common Side Effects of Bimzelx
Bimzelx (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor for plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis, most often causes upper respiratory tract infections (14-16% of patients), oral candidiasis (thrush, 7-13%), and herpes or other infections.[1][2] Injection site reactions like redness or pain occur in about 4%.[1]
Serious Side Effects and Risks
Serious infections, including tuberculosis, require screening before starting—TB cases have led to deaths in trials.[1][2] Inflammatory bowel disease (ulcerative colitis or Crohn's) can worsen or start; monitor for new abdominal pain or bloody stools.[1] Hypersensitivity reactions (rash, swelling) hit 1-2% and may need stopping the drug.[2] Live vaccines are off-limits during treatment.[1]
Side Effects by Condition Treated
In psoriasis trials, 79% reported adverse events (vs. 70% placebo), with infections leading at 28%.[1] Psoriatic arthritis data shows similar rates, plus diarrhea (3%).[2] Axial spondyloarthritis studies note fungal infections up to 11%.[1] Long-term use (up to 144 weeks) keeps infection risks steady without new signals.[2]
How Long Do Side Effects Last?
Most resolve within weeks; infections clear with treatment, candidiasis with antifungals.[1] Injection reactions fade in days. Monitor IBD flares ongoing—discontinue if severe.[2]
Who Gets Side Effects Most?
Higher risk in those with infection history, immunosuppression, or IBD family history. Elderly or diabetics see more infections. No major differences by sex or race in trials.[1][2]
Bimzelx vs. Other IL-17 Inhibitors
More candidiasis than Cosentyx (secukinumab, 3%) or Taltz (ixekizumab, 1-2%) due to dual IL-17 blockade.[3] Similar infection rates overall, but Bimzelx's oral yeast risk stands out.[1]
[1]: Bimzelx Prescribing Information (FDA)
[2]: European Medicines Agency Bimzelx Summary
[3]: DrugPatentWatch.com - Bimekizumab Patent Landscape